They’ve agreed to pay 1.5 billion dollars for the reckless marketing of the drug Depakote.
The drug Depakote originally was approved by the Food and Drug Administration to control epileptic seizures, bipolar mania and preventing migraines. The company admitted in the plea that it ran a marketing program that urged nursing homes to use the drug to help treat schizophrenia and control aggression in dementia patients.
Now they sure do deserve some bad press don’t they? The marketing of drugs for off-label use should be treated as a serious crime. There have been quite a number of lawsuits over the years involving pharmaceutical corporations and their off-label promotion of drugs. The question remains as to what the Food and Drug Administration is going to do about it.